Por: ABC7 Health July 18, 2023
.Nirsevimab, which will be sold under the brand name Beyfortus, is not a vaccine. Vaccines prompt the body to make antibodies to defend against pathogens. Instead, nirsevimab is a form of passive immunity. It's a ready-made antibody that can bind to the virus and block it from infecting healthy cells. The immune system doesn't have to make anything.It's given as a single injection to an infant before RSV season, which usually... + full article
CBS News USA Politics July 17, 2023
The Food and Drug Administration announced Monday it had approved a new kind of immunization to protect babies from . The drug, nirsevimab, is one of two new options doctors hope could soon prevent the leading cause of hospitalization facing American infants.Outside advisers to... + más
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
Pfizer says study shows vaccinating pregnant women protects newborns from RSV | ABC7
New York Post USA Life February 23, 2023
A vaccine to protect against severe cases of Respiratory Syncytial Virus could roll out as early as August. Pfizer has developed RSVpreF, a vaccine to prevent severe cases of RSV, and the Food and Drug Administration is reportedly expediting its review approval process. The FDA... + más
Strong RSV vaccine data lifts hopes after years of futility | WPLG Local 10
ABC7 USA World February 21, 2023
against , could be approved by August.Pfizer, the maker of the vaccine, that the U.S. Food and Drug Administration has accepted its application for review and will make a decision on whether or not to approve the vaccine by August 2023.If approved, RSVpreF would help protect... + más
Forbes USA Tech November 28, 2022
Child in the hospital bed using nebulizer to relieve cough. getty The United States has already plunged into one of the roughest seasons of winter illnesses in decades. After nearly three years of being sequestered, children and adults are back out in crowds, with no masks, no... + más
A 'tripledemic' of flu, RSV and COVID is feared in California | Los Angeles Times
RSV and the ‘Tripledemic’: What you need to know | WGN-TV
CNBC USA Health November 11, 2022
Diane Macdonald Stockbyte Getty ImagesEven healthy infants face a considerable risk of hospitalization from respiratory syncytial virus, according to a large European study published Thursday.Dutch and British scientists, in a study published in Lancet Respiratory Medicine,... + más
Forbes USA Business November 04, 2022
Topline The European Commission on Friday approved the first monoclonal antibody to prevent respiratory syncytial virus (RSV) among all infants and newborns, amid a rise of cases of the highly contagious virus, which can pose a danger to infants and older adults. Intensive care... + más
New injection for newborns to protect against RSV approved in Europe | ABC News
ABC News USA Health November 04, 2022
In what could signal the promise of progress to come for newborn infants at risk for RSV, a new monoclonal antibody is being granted approval in Europe as a preventative measure to protect against RSV infection in very young babies -- those most at risk of contracting the virus... + más
About iurex | Privacy Policy | Disclaimer |